Alfuzosin Treatment in Children and Adolescents With Neurogenic Urinary Bladder Dysfunction

Patients who met the study entry criteria were randomized (2:1:2:1) to one of the 4 dosage groups (Alfuzosin 0.1 mg/kg/day, matching placebo 0.1 mg/kg/day, Alfuzosin 0.2 mg/mg/kg, matching placebo 0.2 mg/kg/day). Patients received their treatment using either solution or tablet formulation depending on age as follows: * Solution to children 2-7 years of age or, children and adolescents 8-16 years of age if they were unable to swallow tablets or they preferred to take the solution or if they had a body weight \< 30kg. The daily dose was devided in 3 doses given at at breakfast, lunch and dinner. * Tablet to children and adolescents 8-16 years of age who were able to swallow tablets and had a body weight ≥ 30kg. The daily dose was devided in 2 doses given at at breakfast and dinner. Patients who have completed the 12-week double-blind phase were offered to continue in the 40-week open-label extension study. * Patients receiving Alfuzosin continued with their dosing regimen. * Patients receiving Placebo were switched to Alfuzosin with a dose corresponding to their randomization dose group. All patients had a one-week follow-up period after last dose intake.